Literature DB >> 7639613

The 5-hydroxytryptamine-nitric oxide connection: the key link in the initiation of migraine?

J R Fozard1.   

Abstract

The evidence for an involvement of 5-hydroxytryptamine (5-HT) and nitric oxide (NO) in the initiation of migraine is reviewed. Based on this, the following scenario is proposed. Endogenous 5-HT, arising perhaps from platelets but more likely from perivascular 5-HT-containing neurons in response to different types of "stress", would activate 5-HT2B/5-HT2C receptors on endothelial cells of the cerebral vasculature to release NO. Nitric oxide would, by directly activating sensory neurons, induce neurotransmitter release, plasma extravasation, pain and hyperalgesia. The result would be induction of the "sterile" inflammatory response, believed to be the key step in the development of migraine.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7639613

Source DB:  PubMed          Journal:  Arch Int Pharmacodyn Ther        ISSN: 0003-9780


  4 in total

1.  Psilocybin dose-dependently causes delayed, transient headaches in healthy volunteers.

Authors:  Matthew W Johnson; R Andrew Sewell; Roland R Griffiths
Journal:  Drug Alcohol Depend       Date:  2011-11-29       Impact factor: 4.492

2.  Pharmacological evidence for the 5-HT7 receptor mediating smooth muscle relaxation in canine cerebral arteries.

Authors:  J A Terrón; A Falcón-Neri
Journal:  Br J Pharmacol       Date:  1999-06       Impact factor: 8.739

Review 3.  Cardiovascular responses produced by 5-hydroxytriptamine:a pharmacological update on the receptors/mechanisms involved and therapeutic implications.

Authors:  Carlos M Villalón; David Centurión
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2007-08-17       Impact factor: 3.000

Review 4.  The role of nitric oxide in brain disorders: Autism spectrum disorder and other psychiatric, neurological, and neurodegenerative disorders.

Authors:  Manish Kumar Tripathi; Maryam Kartawy; Haitham Amal
Journal:  Redox Biol       Date:  2020-05-15       Impact factor: 11.799

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.